ClinicalTrials.gg
RecruitingNCT07289763Updated Jan 26, 2026

Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous Nephropathy

A Phase 2 interventional study of SHR-2173 injection and SHR-2173 injection in Primary Membranous Nephropathy, sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-26.

Sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies in Glomerulonephritis, Membranous with a site in China — 29 open to participants now, 37 under way, 10 of them phase 3. Glomerulonephritis, Membranous · China.

Planned enrollment
26th of 50
75 · median 77
Started
2025
with 7 others
Phase 2
11 of 60
6 open now
Primary completion
2027-08
later than 22 of 36 live
Registered
50th of 60
by date

Among the 60 studies in Glomerulonephritis, Membranous with a site in China, this one is the 26th largest by planned enrollment of the 50 interventional ones that give a count, is one of 8 that started in 2025, is one of 11 in phase 2, reaches primary completion later than 22 of the 36 other live ones, and was the 50th registered.

Glomerulonephritis, Membranous

146 studies on the registry are indexed under Glomerulonephritis, Membranous; 60 are open to participants now.

Browse Glomerulonephritis, Membranous studies →

Open to participants now

29 of the 60 studies in Glomerulonephritis, Membranous with a site in China are open now. Recruiting first, the newest first:

23 more — sign in →

All 29 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 41 Glomerulonephritis, Membranous studies recruiting now, 14 (34%) set no upper age limit and 14 (34%) stop at 75 or younger; 8 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Glomerulonephritis, Membranous with a site in China, or all of them as a file.
02

Study summary

To investigate the safety, efficacy, pharmacokinetics, and pharmacodynamics of SHR-2173 injection in patients with primary membranous nephropathy

03

Conditions studied

  • Primary Membranous Nephropathy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-75 years, regardless of gender;
  2. Weight ≥40.0 kg at screening;
  3. Diagnosed as primary membranous nephropathy through kidney .

Exclusion criteria

Exclusion Criteria:

  1. Secondary membranous nephropathy.
  2. Subjects developed rapidly progressive glomerulonephritis or required kidney transplantation.
  3. Subjects who have undergone kidney dialysis in the previous 12 months or are expected to require dialysis during the study period.
  4. Subjects who have a malignant tumor or a history of malignant tumor
  5. Subjects who have undergone major surgery within the previous 3 months, or plan to undergo major surgery during the study period.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    Treatment group A

    Drug: SHR-2173 injection

  • Experimental
    Treatment group B

    Drug: SHR-2173 injection

  • Experimental
    Treatment group C

    Drug: SHR-2173 injection

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse events

    Time frame: Week0, 2, 4, 8, 12,16, 20, 24, 28, 32, 36, 40, 48 52

  2. 12-lead ECG

    Time frame: Week4, 8, 12, 24, 28, 36, 52

Secondary outcomes

  1. The proportion of subjects who achieved overall response (including complete response (CR) and partial response (PR)).

    Time frame: Week 12, 24, 36, 52

  2. The proportion of subjects who achieved CR

    Time frame: Week 12, 24, 36, 52

  3. The proportion of subjects who achieved PR

    Time frame: Week 12, 24, 36, 52

07

Study locations

1 of 1 sites recruiting
  • General hospital of eastern theater command
    Nanjing, Jiangsu 210002, China
    Recruiting
    • Liangjing Lv · Principal investigator
    • Zhihong Liu · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Aug 2027, 20 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2025
First posted
Dec 17, 2025
StartActual
Dec 31, 2025
Primary completionEst.
Aug 2027
CompletionEst.
Sep 2027
Last update
Jan 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07289763
Responsible party
Sponsor
First posted
Dec 17, 2025
Start date
Dec 31, 2025
Primary completion
Aug 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Jan 26, 2026

Study contacts

Zhe Zhang
Contact
zhe.zhang@hengrui.com
+0518-81220121

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SHR-2173

Start the discussion